Intellectual Property Rights in Pharmaceutical Test Data

Intellectual Property Rights in Pharmaceutical Test Data
Author :
Publisher : Springer Nature
Total Pages : 236
Release :
ISBN-10 : 9783031294365
ISBN-13 : 303129436X
Rating : 4/5 (36X Downloads)

Book Synopsis Intellectual Property Rights in Pharmaceutical Test Data by : Adam Buick

Download or read book Intellectual Property Rights in Pharmaceutical Test Data written by Adam Buick and published by Springer Nature. This book was released on 2023-05-12 with total page 236 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book considers the intellectual property protection of clinical test data that has been submitted to governments, in particular through test data exclusivity rights. It focuses on how these intellectual property rights first emerged in the early 1980s, how they have globalised over the past four decades, and what impact they have had upon access to medicine. This book makes a number of significant and original contributions to the literature around the protection of submitted test data. First, the book draws upon the theory of regulatory globalisation to provide an explanation of how intellectual property rights in submitted pharmaceutical test data have become nearly ubiquitous in the legal systems of most major economies. Second, through a comprehensive analysis and synthesis of provisions on the protection of submitted test data in free trade agreements, as well as a comparison of a range of national approaches to the protection of submitted test data, it reveals the broader global regulatory pattern that has given rise to these intellectual property rights. Third, by analysing data on drug approvals in the US, it provides an empirical insight into the impact of test data exclusivity in national pharmaceutical markets. Fourth, the book covers a number of developments regarding test data exclusivity that have occurred as a result of responses to the COVID-19 pandemic, both at the national level as well as at the World Trade Organisation (WTO). This book will appeal to academics researching the intersection of intellectual property and the life sciences, civil society activists working to promote access to medicines, and students (particularly those at the post-graduate level) studying the relationship between intellectual property and medicine.


Intellectual Property Rights in Pharmaceutical Test Data Related Books

Intellectual Property Rights in Pharmaceutical Test Data
Language: en
Pages: 236
Authors: Adam Buick
Categories: Law
Type: BOOK - Published: 2023-05-12 - Publisher: Springer Nature

DOWNLOAD EBOOK

This book considers the intellectual property protection of clinical test data that has been submitted to governments, in particular through test data exclusivi
Access to Medicine Versus Test Data Exclusivity
Language: en
Pages: 269
Authors: Owais H. Shaikh
Categories: Law
Type: BOOK - Published: 2016-07-25 - Publisher: Springer

DOWNLOAD EBOOK

This book explores the concept of test data exclusivity protection for pharmaceuticals. Focusing on Art 39(3) of the WTO Agreement on Trade-Related Aspects of I
Pharmaceutical Test Data Exclusivity
Language: en
Pages: 250
Authors: John C. Todaro
Categories: Law
Type: BOOK - Published: 2022-08-12 - Publisher: Kluwer Law International B.V.

DOWNLOAD EBOOK

Data exclusivity gives pharmaceutical companies a limited period of time in which clinical test data are exclusive to the innovator. Internationally, however, a
Sharing Clinical Trial Data
Language: en
Pages: 236
Authors: Institute of Medicine
Categories: Medical
Type: BOOK - Published: 2015-04-20 - Publisher: National Academies Press

DOWNLOAD EBOOK

Data sharing can accelerate new discoveries by avoiding duplicative trials, stimulating new ideas for research, and enabling the maximal scientific knowledge an
Contemporary Issues in Pharmaceutical Patent Law
Language: en
Pages: 271
Authors: Bryan Mercurio
Categories: Law
Type: BOOK - Published: 2017-02-17 - Publisher: Routledge

DOWNLOAD EBOOK

This collection reflects on contemporary and contentious issues in international rulemaking in regards to pharmaceutical patent law. With chapters from both wel